Rare dermatologic diseases are neglected in drug development
(© Orphanews 2019.04.12)
A new study on rare dermatologic disease show that they have been rather neglected compared to other conditions.
Indeed, out of 428 rare dermatologic diseases, the paper finds that only 41 diseases (10%) were undergoing a total of 255 active clinical trials.
Of those trials, 104 (41%) were industry-funded. As a whole, phase 2 and 3 clinical trials were conducted for 5% only of rare dermatologic diseases.
These extremely low numbers indicate that very few are likely to reach regulatory approval.
The authors explain this lack of investment from the pharmaceutical sector by expected lower economic benefits associated with rare dermatologic diseases, and the lack of knowledge regarding skin disease pathophysiology, which then results in greater difficulties in establishing research project and demonstrating its efficacy.